Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 28586.53 Crore) operating in Pharmaceuticals sector.
By ETMarkets.com | Updated:
BCCL
Promoters held 46.1 per cent stake in the company as of Sept 30, 2020, while FIIs held 12.4 per cent, DIIs 28.9 per cent and public and others 12.6 per cent.
Motilal Oswal has given a buy rating to Ipca Laboratories with a target price of Rs 2680. The share price moved down by 5.35 per cent from its previous close of Rs 2264.80. The stock’s last traded price is Rs 2143.70.
Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 28586.53 Crore) operating in Pharmaceuticals sector.
Financials For the quarter ended 30-09-2020, the company reported a Consolidated sales of Rs 1361.10 Crore, down 11.29 % from last quarter Sales of Rs 1534.40 Crore and up 6.01 % from last year same quarter Sales of Rs 1283.90 Crore Company reported net profit after tax of Rs 268.62 Crore in latest quarter.
Investment Rationale The brokerage remains positive on IPCA on the back of: a) traction in new APIs as well as continued momentum in existing API molecules – supported by opportunities arising from geopolitical tensions, b) a superior performance in DF, c) products launches under its own label in the UK, and d) increased backward integration.
Promoter/FII Holdings Promoters held 46.1 per cent stake in the company as of Sept 30, 2020, while FIIs held 12.4 per cent, DIIs 28.9 per cent and public and others 12.6 per cent.
